Literature DB >> 8678767

The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.

D T Lai1, M Fulham, M S Stephen, K M Chu, M Solomon, J F Thompson, D M Sheldon, D W Storey.   

Abstract

OBJECTIVE: To compare the accuracy of whole-body position emission tomography (PET)using [18F]fluorodeoxyglucose (FDG) with conventional radiological imaging techniques in identifying operable colorectal cancer metastases to the liver.
DESIGN: A double-blind comparative study of FDG-PET as the criterion standard vs conventional radiological imaging methods as the criterion standard, in staging of recurrent colorectal cancer.
SETTING: Institutional practice in a tertiary referral center. PATIENTS: Thirty-four consecutive patients with suspected colorectal cancer metastases recruited for the study between May 1993 and October 1994.
INTERVENTIONS: Conventional radiological methods of cancer staging included abdominal computed tomography (CT) (n = 34), chest x-rays (n = 15), and chest CT (n = 19) to evaluate extrahepatic disease. Twenty-seven patients were subsequently considered to have apparently isolated cancer metastases to the liver. Anatomical resectability was assessed by magnetic resonance imaging (n = 24) or CT angiography (n = 3) in all study patients. The FDG-PET studies (n = 34) were performed within 8 weeks of conventional radiological imaging. MAIN OUTCOME MEASURES: Malignancy of suspected lesions detected by means of FDG-PET and conventional radiological imaging was confirmed by histopathologic examination of resected specimens and percutaneous biopsy specimens and by serial CT scans demonstrating progression of disease.
RESULTS: Unsuspected extrahepatic malignant disease that was missed by conventional radiological imaging was detected by FDG-PET in 11 patients (32%). The PET-detected extrahepatic malignant disease included retroperitoneal nodal metastases (n = 6), pulmonary metastases (n = 3), and locoregional cancer recurrences (n = 2). The additional information afforded by PET consequently had an influence on the clinical management in 10 patients (29%).
CONCLUSIONS: The FDG-PET method enabled selection of patients with apparently curable colorectal cancer metastases to the liver for hepatic resection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8678767     DOI: 10.1001/archsurg.1996.01430190025007

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  28 in total

1.  Letter to the editor

Authors: 
Journal:  Ann Surg       Date:  2000-11       Impact factor: 12.969

Review 2.  The impact of new technology on surgery for colorectal cancer.

Authors:  G B Makin; D J Breen; J R Monson
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

3.  Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer.

Authors:  H Furukawa; H Ikuma; A Seki; K Yokoe; S Yuen; T Aramaki; S Yamagushi
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

Review 4.  Restaging of colorectal cancer and PET/CT.

Authors:  Alev Çınar; Esra Arzu Gençoğlu; Meliha Korkmaz
Journal:  Ulus Cerrahi Derg       Date:  2013-06-01

5.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

6.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

7.  Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?

Authors:  Markus Selzner; Thomas F Hany; Peer Wildbrett; Lucas McCormack; Zakiyah Kadry; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

8.  Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

Authors:  Felix G Fernandez; Jeffrey A Drebin; David C Linehan; Farrokh Dehdashti; Barry A Siegel; Steven M Strasberg
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

9.  Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.

Authors:  Katja Ott; Wolfgang A Weber; Ulrich Fink; Hermann Helmberger; Karen Becker; Hubert J Stein; James Müller; Markus Schwaiger; Jörg Rüdiger Siewert
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

10.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.

Authors:  D L Francis; A Freeman; D Visvikis; D C Costa; S K Luthra; M Novelli; I Taylor; P J Ell
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.